Beom-Su Kim1, Moon-Ki Choi2, Jung-Hoon Yoon3, Jun Lee4. 1. Wonkwang Bone Regeneration Research Institute, Wonkwang University, Daejeon Korea; Bonecell Biotech Inc., Daejeon, Korea. 2. Department of Oral and Maxillofacial Surgery, Wonkwang University, Iksan, Korea. 3. Department of Oral and Maxillofacial Pathology, Daejeon Dental Hospital, Wonkwang University, Daejeon, Korea. 4. Department of Oral and Maxillofacial Surgery, Daejeon Dental Hospital, Wonkwang University, Daejeon, Korea. Electronic address: Omslee@wku.ac.kr.
Abstract
OBJECTIVE: The aim of this study was to evaluate the in vivo osteogenic potential of biphasic calcium phosphate (BCP), bone morphogenetic protein 2 (BMP-2), and/or mesenchymal stem cell (MSC) composites by using a rabbit calvarial defect model. STUDY DESIGN: Bone formation was assessed by using three different kinds of implants in rabbit calvarial defects, BCP alone, BCP/recombinant human (rh) BMP-2, and BCP/rhBMP-2/MSCs composite. The implants were harvested after 2 or 8 weeks, and the area of new bone formation was quantified by micro-computed tomography (micro-CT) and histologic studies. RESULTS: The highest bone formation was achieved with the BCP/rhBMP-2/MSCs treatment, and it was significantly higher than that achieved with the empty or BCP-alone treatment. The quantity of new bone at 8 weeks was greater than at 4 weeks in each group. The relative density of osteocalcin immunoreactivity also increased during this interval. CONCLUSIONS: These results indicate that the combination of BCP, rhBMP-2, and MSCs synergistically enhances osteogenic potential during the early healing period and could be used as a bone graft substitute.
OBJECTIVE: The aim of this study was to evaluate the in vivo osteogenic potential of biphasic calcium phosphate (BCP), bone morphogenetic protein 2 (BMP-2), and/or mesenchymal stem cell (MSC) composites by using a rabbit calvarial defect model. STUDY DESIGN: Bone formation was assessed by using three different kinds of implants in rabbit calvarial defects, BCP alone, BCP/recombinant human (rh) BMP-2, and BCP/rhBMP-2/MSCs composite. The implants were harvested after 2 or 8 weeks, and the area of new bone formation was quantified by micro-computed tomography (micro-CT) and histologic studies. RESULTS: The highest bone formation was achieved with the BCP/rhBMP-2/MSCs treatment, and it was significantly higher than that achieved with the empty or BCP-alone treatment. The quantity of new bone at 8 weeks was greater than at 4 weeks in each group. The relative density of osteocalcin immunoreactivity also increased during this interval. CONCLUSIONS: These results indicate that the combination of BCP, rhBMP-2, and MSCs synergistically enhances osteogenic potential during the early healing period and could be used as a bone graft substitute.
Authors: Cindy Kelder; Jolanda M A Hogervorst; Daniël Wismeijer; Cornelis J Kleverlaan; Teun J de Vries; Astrid D Bakker Journal: Int J Mol Sci Date: 2020-04-30 Impact factor: 5.923